Is Pemvidutide legal in the US?
Not yet; it is still in trials.
BSome human evidenceIn clinical trialsas of 2026-10-27
Not approved by the FDA or any other regulator for any use. Pemvidutide is an investigational once-weekly injection from Altimmune; after the phase 2b IMPACT trial in metabolic dysfunction-associated steatohepatitis (MASH), a phase 3 MASH trial (PERFORMA) began in July 2026. Phase 2 trials have also covered obesity, alcohol use disorder and alcohol-associated liver disease.
Read the full Pemvidutide page
More on Pemvidutide
Citations
- StatPearls: glucagon-like peptide-1 receptor agonists ncbi.nlm.nih.gov
- 2025, Lancet: safety and efficacy of weekly pemvidutide versus placebo for MASH, 24-week results of the IMPACT phase 2b trial doi.org
- Browne 2025, JHEP Reports: safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease, randomized controlled trial doi.org
- ClinicalTrials.gov: NCT07795164, PERFORMA phase 3 trial of pemvidutide in MASH clinicaltrials.gov
Reference information only, not medical advice. Drawn from the Pemvidutide article, fact-checked against the cited sources. No dosing anywhere on this site.